Sirnaomics Ltd. · HKEX:2257
Sirnaomics — H1 2022 Earnings Presentation
29 slides from Sirnaomics's earnings presentation, 2022

Slide 1: Sirnaomics Ltd. 2022 Interim Result Presentation
Sirnaomics Ltd. [2257.HK] (Incorporated in the Cayman Islands with limited liability) 2022 Interim Result Presentation 0

Slide 2: Disclaimer
Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by representatives of Sirnaomics Ltd. (the “Company”) for use in presentations by

Slide 3: Presenters
Presenters Patrick Lu 陆阳, PhD Michael V. Molyneaux, MD, MBA David Mark Evans, PhD Founder, Chairman of the Board, Executive Executive Director, CMO Executive Director, CSO Director, President & CEO 28+ years of experience 20+ years of experience 25+ years of experience Dmitry Samarsky, PhD Edward Wa

Slide 4: Agenda
Agenda 01 - Company Overview 02 - Pipeline Updates 03 - Future Milestones and Catalysts 04 - Financial Highlights 3

Slide 5: Company Overview
sirna@mics Advancing RNAi Therapeutics Company Overview

Slide 6: Sirnaomics: A RNA Therapeutic Innovator on a Global Stage
Sirnaomics: A RNA Therapeutic Innovator on a Global Stage Proprietary Delivery Expanding Clinical Broad Established Technology Platforms Pipelines therapeutic utility Manufacturing Facilities Polypeptide nanoparticle (PNP) Clinical assets STP705 and Oncology, fibrosis, medical Large-scale GMP-compli

Slide 7: Major Accomplishments Year to Date
Major Accomplishments Year to Date Jan 22 Feb 22 Mar 22 Apr 22 May 22 Jun 22 Jul 22 Aug 22 Received regulatory clearance Interim data from from the Taiwan Ministry of Health Become a constituent STP705 Phase II and Welfare (TMHW) of IND of Hang Seng family clinical trial for the application to comme

Slide 8: Pipeline Updates
sirna@mics Advancing RNAi Therapeutics Pipeline Updates

Slide 9: Delivery Technology Platforms and Therapeutic Areas
Delivery Technology Platforms and Therapeutic Areas PNP Platform: GalNAc Platform: (Clinical Stage) (Clinical Candidate) CPP GalAhead® siRNA PDoV-GalNAc HKP and HKP(+H) are well suited for siRNA Therapeutics or mRNA Therapeutics and Vaccine Deliveries mRNA Cancer Fibrosis Diseases Viral Infections L

Slide 10: Broad and Deep Product Pipeline
Broad and Deep Product Pipeline Delivery IND Candidate Gene Targets Indications Pre-clinical IND Phase I Phase II Phase III Rights Platform Enabling US isSCC China (MRCT)2 Global BCC US Global STP705* TGF-β1/COX-2 PNP-IT US Liver Cancer1 (Basket) ** China (MRCT)3 Global Liver Cancer, combo with anti

Slide 11: Significant Market Potential & Commercialisation Opportunity
Significant Market Potential & Commercialisation Opportunity ◼ NMSC: BCC and SCC account for majority of NMSCs with more than five million newly diagnosed cases in the U.S. every year ◼ isSCC (US): 1.3mn / 3.4mn new cases in 2020 / 20301 ◼ BCC (US): 2.4mn / 4.2mn new cases in 2020 / 20301 Large Unme

Slide 12: STP705 - isSCC
STP705 - isSCC ◼ Positive Phase IIa Clinical Readouts for isSCC treatment: ◼ Overall, 76% of subjects across all groups (25 subjects) achieved Complete Histological Clearance ◼ Within the 2 higher dosing groups (9/10 subjects), 90% of them have achieved Complete Histological Clearance ◼ No significa

Slide 13: STP705 - Facial isSCC
STP705 - Facial isSCC Phase I/II in Progress Protocol, study design and endpoints ◼ In August 2022, we have dosed our first patient in the clinical trial. ◼ Expansion into facial isSCC is evidence of the excellent safety profile of STP705, demonstrated in our Phase IIa clinical study for the treatme

Slide 14: STP705 - BCC
STP705 - BCC Phase II in Progress Cohort A: 30 μg Cohort B: 60 μg Cohort C: 90 μg Cohort D: 120 μg Cohort E: 180 μg (N=5) (N=5) (N=5) (N=5) (N=5) 1/5 3/5 3/5 2/5 5/5 Histological Clearance 20% 60% 60% 40% 100% Average Skin Response Scores Pre-treatment 3.2 2.8 2.6 Scores not reported until final rep

Slide 15: STP705 – Fat Reduction
STP705 – Fat Reduction Pre-Clinical Minipig Model Efficacy Validation Phase I in Progress Control group Protocol, study design and endpoints ◼ In May 2022, we have launched a Phase I clinical trial STP705 of STP705 in adults undergoing abdominoplasty for Treatment group submental fat reduction. ◼ Pr

Slide 16: STP707 - Solid Tumors
STP707 - Solid Tumors In Situ or Metastatic Liver Cancer Phase I in Progress ◼ In November 2011, we initiated a Phase I clinical trial for solid tumors in the U.S. ◼ Protocol: multi-center open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activ

Slide 17: STP707 - Liver Fibrosis
STP707 - Liver Fibrosis Primary Sclerosing Cholangitis (PSC) Phase Phase II in in Progress Progress ◼ Obtained US FDA approval of IND application for Phase I clinical trail of STP707 in treatment of PSC by intravenous administration ◼ Clinical trial for PSC launched in 1Q22, with interim data expect

Slide 18: STP355 - TGF-β1/VEGFR2 RNAi Therapeutics
STP355 - TGF-β1/VEGFR2 RNAi Therapeutics Antitumor results:C57BL16 melanoma model, Antitumor results:MDA-MB-231 xenograft breast cancer N = 6, P<0.05 model, N = 6, P<0.05 STP355 STP355 Antitumor results:C57BL16 mouse colon cancer model Antitumor results:C57BL16 mouse colon cancer model with MC38-hPD

Slide 19: GalAhead™ Pipeline
GalAhead™ Pipeline Candidate IND Drug Technology Target Indication Discovery IND Nomination Enabling STP122G mxRNA Factor XI Anticoagulation/Thrombosis STP125G mxRNA APOC3 Hypertriglyceridemia STP144G mxRNA Complement Factor B Complement-mediated diseases STP145G mxRNA Complement C5 Complement-media

Slide 20: STP122G: Factor XI knockdown in non-human primates (33 wks)
STP122G: Factor XI knockdown in non-human primates (33 wks) Long-Lasting Target Knockdown Effect and Strong Therapeutic Benefit STP122G therapeutic effect at 33 weeks Strong Therapeutic Benefit Groups: Activated Partial Thromboplastin Time All groups 2x, 3x Group: 3x Prothrombin Time 23 weeks 15 wee

Slide 21: STP251G: APOC3 & TMPRSS6 mRNA Knockdown In Vivo
STP251G: APOC3 & TMPRSS6 mRNA Knockdown In Vivo APOC3: mRNA in Liver Tissues TMPRSS6: mRNA in Liver Tissues 72% 87% 87% 96% High Potency • Comparable KD between single and multiple treatments • Successful KD of two hepatocyte-specific targets with both single and multiple treatments Animal model: hu

Slide 22: Well-Established Clinical Manufacturing Capabilities
Well-Established Clinical Manufacturing Capabilities Guangzhou Pilot Plant Facility ◼ Pilot Plant fully operational since 2022. ◼ Formulation F&F of PNP & GalNAc products. ◼ ~50,000 human injectables vials annually. ◼ 8 batches drug product produced to date. ◼ QMS GMP regulatory compliant. ◼ CMC Pro

Slide 23: Global Mfg. Collaboration & Supply Chain Establishment
Global Mfg. Collaboration & Supply Chain Establishment Well established /verified cGMP process Future commercial manufacturing sites Guangzhou HKP facility siRNA PNP ◼ PNP manufacturing process - microfluidic technology - continuously improving to support pipeline expansion. ◼ Well established cGMP

Slide 24: Future Milestones and Catalysts
Part 3 Future Milestones and Catalysts 23

Slide 25: Anticipated Milestones and Catalysts
Anticipated Milestones and Catalysts Candidates 1H 2022 2H 2022 2023 Interim data isSCC readout Interim data 100% complete Interim data BCC readout response in Cohort 5 readout Final data readout Initiate Phase I trial in STP705 Liver Cancer (Basket) Taiwan Fat sculpting Initiate Phase I trial First

Slide 26: Financial Overview
sirna@mics Advancing RNAi Therapeutics Financial Overview

Slide 27: Profit and Loss
Profit and Loss 1. Changes in fair value of financial liabilities at FVTPL: Jun 30 Jun 30 decreased to US$2.9m from US$12.4m (US$9.5m or 77% Ref 2022 2021 decrease) primarily due to conversion of the Company’s preferred US$ (m) US$ (m) shares to ordinary shares upon IPO on December 30, 2021. Other i

Slide 28: Cash flow
Cash flow For six months For six months 1. Net cash used in operating activities: increased ended Jun 30, 2022 ended Jun 30, 2021 to US$45.4m from US$19.4m (US$26.0m or 134% increase) primarily due to the expansion of the Ref cash flow US$ (m) US$ (m) US$ (m) US$ (m) Group’s research and development

Slide 29: Q&A
SITna@mics icing RNAi Therapeutic: Q&A
Source: Internet Archive copy of sirnaomics.com





